Loading clinical trials...
Loading clinical trials...
The objective of this study is to investigate how the intraocular pressure (IOP)-lowering effect of the L-PPDS is altered by adjunctive Xalatan therapy.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Mati Therapeutics Inc.
Collaborators
NCT07217678 · Glaucoma, Open-Angle Glaucoma, and more
NCT07354477 · Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG), and more
NCT07390890 · Primary Open Angle Glaucoma, Ocular Hypertension
NCT05902871 · Primary Open Angle Glaucoma, Ocular Hypertension, and more
NCT07218796 · Cataract, Glaucoma, and more
Menlo Park
Menlo Park, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions